Intra Cellular Therapies | Umsatzkosten



Cost Of Sales Veränderung Datum
Acadia Pharmaceuticals USD 21.8M 2.95M 2024-12
ALKERMES USD 62.12M 984K 2024-12
Biogen USD 583.5M 55.2M 2024-12
Bristol-Myers Squibb USD 3.21B 356M 2024-12
Cytokinetics 463K 79.14M 2024-09
Gilead Sciences USD 1.58B 7M 2024-12
Halozyme Therapeutics USD 42.06M 7.37M 2024-12
J&J USD 7.11B 151M 2024-12
Neurocrine Biosciences USD 9.3M 1.3M 2024-12
Novartis USD 3.31B 73M 2024-12
Prothena 970K 4.78M 2024-09
RedHill Biopharma USD 702K 0 2024-06
Supernus Pharmaceuticals USD 17.2M 385K 2024-12
United Therapeutics USD 75.9M 7.2M 2024-12



Intra Cellular Therapies Umsatzkosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Apr 2025.